Aug 072020
 

By Talent4Boards Team

Talent4Boards - Great Talent builds Great Boards

– USA, CA – Eidos Therapeutics, Inc. (Nasdaq: EIDX), a clinical-stage biopharmaceutical company focused on addressing the large and growing unmet need in diseases caused by transthyretin amyloidosis, today announced the addition of Suzanne Hooper, the former EVP and general counsel of Jazz Pharmaceuticals, and Duke Rohlen, the CEO and ...

Eidos Therapeutics appoints Suzanne Hooper and Duke Rohlen to its Board of Directors

Eidos Therapeutics appoints Suzanne Hooper and Duke Rohlen to its Board of Directors

From:: Eidos Therapeutics appoints Suzanne Hooper and Duke Rohlen to its Board of Directors

Sorry, the comment form is closed at this time.